Objective To explore the clinical effects and safety of piperazine ferulate combined with irbesartan in treatment of chronic renal failure.Methods A total of 62 patients suffering chronic renal failure to receive treatment in our hospital were selected as research subjects and divided randomly into an observation group and a control group (n =31,respectively).The control group was administered with piperazine ferulate on the basis of conventional treatment,and the observation group was administered with irbesartan on the basis of the treatment in the control group.The treatment time period was two months.The clinical effects,renal function indicators before and after the treatment,the adverse reactions,and the quality of life were observed and compared between the two groups.Results After the treatment,the curative effects and total effective rate in the observation group were higher than those in the control group (P ＜ 0.05);the serum creatinine (Cr),blood urea nitrogen (BUN) and urinary protein (PRO) in both groups decreased significantly,and creatinine clearance rate (Ccr) increased significantly;the Cr,BUN and PRO in the observation group were significantly lower than those in the control group,while the Ccr was significantly higher than that in the control group(P ＜ 0.05).There was no significant difference in adverse reaction between the two groups (P ＞ 0.05).The physiological function (PF),role physical (RP),body pain (BP),general health (GH),and vitality (VT) scores in the observation group were significantly higher than those in the control group (P ＜ 0.05).Conclusion Piperazine ferulate combined with irbesartan in the treatment of chronic renal failure has good clinical effects and high safety,and has positive significance in the improvement of the life quality of the patients;it is worthy of popularization and application.
国家科技期刊平台
NSTL
维普
万方数据
